ALINT Stock Overview
Provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
IntegraGen SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.51 |
| 52 Week High | €0.93 |
| 52 Week Low | €0.43 |
| Beta | 0.18 |
| 1 Month Change | 4.51% |
| 3 Month Change | -2.86% |
| 1 Year Change | -42.95% |
| 3 Year Change | -53.38% |
| 5 Year Change | -52.34% |
| Change since IPO | -94.38% |
Recent News & Updates
Why Investors Shouldn't Be Surprised By IntegraGen SA's (EPA:ALINT) Low P/S
Dec 14
Lacklustre Performance Is Driving IntegraGen SA's (EPA:ALINT) Low P/S
Aug 28Recent updates
Shareholder Returns
| ALINT | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -3.8% | 1.2% | 0.6% |
| 1Y | -43.0% | -30.3% | -4.0% |
Return vs Industry: ALINT underperformed the French Biotechs industry which returned -29.8% over the past year.
Return vs Market: ALINT underperformed the French Market which returned -3.5% over the past year.
Price Volatility
| ALINT volatility | |
|---|---|
| ALINT Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.8% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALINT's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALINT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 44 | Bernard Courtieu | integragen.com |
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company’s genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts.
IntegraGen SA Fundamentals Summary
| ALINT fundamental statistics | |
|---|---|
| Market cap | €3.38m |
| Earnings (TTM) | -€24.71k |
| Revenue (TTM) | €11.08m |
0.3x
P/S Ratio-136.6x
P/E RatioIs ALINT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALINT income statement (TTM) | |
|---|---|
| Revenue | €11.08m |
| Cost of Revenue | €6.74m |
| Gross Profit | €4.34m |
| Other Expenses | €4.36m |
| Earnings | -€24.71k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0037 |
| Gross Margin | 39.16% |
| Net Profit Margin | -0.22% |
| Debt/Equity Ratio | 45.8% |
How did ALINT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 04:50 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
IntegraGen SA is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Guillot | Kepler Cheuvreux |
| Arnaud Guérin | Portzamparc BNP Paribas |